Olaparib vs Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer

Complete Radiologic Response in Metastatic Castration-Resistant Prostate Cancer Treated with Cabazitaxel

Cabazitaxel in the Management of Metastatic Castration-resistant Prostate Cancer Progressing After Docetaxel-based Chemotherapy

Docetaxel is the guideline-recommended first-line chemotherapy in men with castration-resistant prostate cancer (CRPC). Despite its proven survival benefit, however, all patients will progress after a mean interval of six to eight months. Recently, the FDA approved cabazitaxel and abiraterone acetate as effective second-line treatment options in this clinical scenario. By comparison with mitoxa...

Complete Radiologic Response in Metastatic Castration-Resistant Prostate Cancer Treated with Cabazitaxel

Dear Editor, About 20-40% of patients who undergo primary therapy for early-stage prostate cancer, experience biochemical relapse of which 30-70% develop metastatic disease within 10 years1 and the majority will become resistant to castration (CRPC). Since 2004, docetaxel has been the first-line cytotoxic treatment in treating metastatic CRPC. However, many mCRPC patients eventually become resi...

Prognostic factors in men with metastatic castration-resistant prostate cancer treated with cabazitaxel

Background Treatment selection for men with metastatic castration-resistant prostate cancer (mCRPC) has become increasingly challenging with the introduction of novel therapies at earlier disease stages. The purpose of this study was to identify prognostic factors for overall survival (OS) and PSA response in patients with mCRPC treated with cabazitaxel. Results 224 mCRPC patients were includ...

Prolonged therapy with cabazitaxel in an octogenarian with metastatic castration-resistant prostate cancer.

Case Report A 73-year-old man with a past medical history of diabetes and gout was noted by his urologist to have an abnormal digital rectal examination in April 1997. Core biopsies of the prostate were performed, revealing Gleason 7 (4 3) disease comprising roughly 50% of 6 pecimens. The patient was treated with brachytherapy, and the paient’s prostatic-specific antigen (PSA) level declined to...